HRT and Heart Health

Educational only. Not medical advice. Cardiovascular risk assessment is individualized. If you have existing heart disease or significant risk factors, discuss HRT with a cardiologist in addition to your prescribing clinician.

Before 2002, doctors prescribed HRT partly to protect the heart. After 2002, they stopped prescribing it partly because they feared it would harm the heart. Both positions were wrong. Or more precisely, both were oversimplified versions of a picture that depends entirely on one variable: when you start.

HRT initiated within 10 years of menopause may actively protect your cardiovascular system. HRT initiated 20 years later may increase risk. The timing hypothesis is not a fringe theory - it is central to every major clinical guideline. And it means the answer to “is HRT good or bad for my heart?” is “it depends on when you start it.”

WHI reanalysis by age group (Rossouw et al., JAMA 2007):

Women aged 50 to 59 (within ~10 years of menopause): combined therapy showed a trend toward reduced coronary heart disease (hazard ratio 0.76, CI 0.50-1.16). Estrogen-only showed an even stronger signal (hazard ratio 0.59, CI 0.35-1.00).

Women aged 60 to 69: neutral. No significant increase or decrease.

Women aged 70 to 79: increased coronary risk, particularly in the first year.

The Danish Osteoporosis Prevention Study (DOPS) randomized recently menopausal women (average age 50, within 2 years of menopause) and found that after 10 years, the HRT group had a significantly reduced composite risk of death, heart failure, or myocardial infarction (hazard ratio 0.48, CI 0.26-0.87) with no increased risk of stroke, VTE, or cancer.

The WHI age-stratified data and DOPS together paint a consistent picture: HRT started near menopause onset in healthy women appears cardiovascularly protective. HRT started decades later does not.

Before menopause, estrogen promotes nitric oxide-mediated vasodilation, reduces LDL oxidation, maintains arterial flexibility, and supports healthy endothelial function. When estrogen declines, these protections diminish and atherosclerosis can accelerate.

If HRT is started while vessels are still relatively healthy (within the timing window), estrogen resumes its protective effects. If started after years of estrogen deficiency when significant plaque has accumulated, estrogen may destabilize existing plaque - the proposed mechanism for increased cardiovascular events in older WHI participants.

If you are within 10 years of menopause or under 60: the cardiovascular data is reassuring and may be favorable. HRT is not prescribed for heart protection alone, but the cardiovascular effect weighs in favor of treating your symptoms.

If you are more than 10-15 years past menopause or over 65: HRT initiation requires more careful individual assessment and ideally cardiology input.

If you started HRT at 52 and are now 65: the question is whether to continue (generally favorable) versus starting de novo (more cautious). Continuing established HRT has a different cardiovascular profile than initiating in an estrogen-naive older woman.

Transdermal estrogen has a more favorable cardiovascular profile than oral in all age groups because it does not increase VTE risk or significantly affect clotting factors.

The Transdermal Advantage For Cardiovascular Safety

Transdermal estrogen carries lower VTE risk than oral because it bypasses liver first-pass metabolism. See Forms of HRT for the full route comparison.

For women with any cardiovascular risk factor - hypertension, elevated lipids, diabetes, obesity, family history of premature cardiovascular disease - transdermal estrogen is the preferred route. This preference becomes stronger with age. A 55-year-old with well-controlled hypertension starting HRT should be on transdermal, not oral. A 65-year-old continuing established HRT should be on transdermal if not already.

The cardiovascular case for transdermal is strong enough that some menopause specialists default to transdermal for all patients regardless of risk factors, reasoning that the VTE and metabolic advantages come at minimal cost (patches and gels are modestly more expensive than generic oral but widely available).

Monitoring Cardiovascular Health On HRT

Baseline cardiovascular assessment should include blood pressure, fasting lipids, and fasting glucose. Repeat lipids at 6 to 12 months after starting (particularly important for oral estrogen users). Annual blood pressure monitoring. Report any new chest symptoms, shortness of breath, or exercise intolerance promptly.

• Given my age and time since menopause, how do the cardiovascular data apply to me?
• Do I have cardiovascular risk factors that affect the HRT decision?
• Should I use transdermal rather than oral based on my cardiovascular profile?
• Should I have cardiovascular screening before starting?